St. Louis-based Cofactor will use the National Cancer Institute's clinical specimens in order to validate its Paragon assay platform.
In PNAS this week: half-a-dozen Aspergillus sequenced, genetic similarities between friends and classmates, and more.
In PNAS this week: epigenetic differences in wild, farmed Coho salmon; RNA editing in immune cells; and more.
Researchers test gene therapy targeting a different cancer protein in a new trial, the New York Times reports.
In PNAS this week: genes selected for in potato domestication, method sequencing and haplotyping analysis on single cells, and more.
The Jackson Laboratory and Seven Bridges have won a $2 million grant to create a platform for coordinating research with patient-derived tumor xenograft data sets.
The company is developing a companion diagnostic to identify head and neck cancer patients most likely to benefit from Erbitux.
The firm plans to develop and evaluate the utility of an ethnically diverse group of metastatic prostate cancer patient-derived xenograft models.
DxTerity aims to develop a genomic blood test to identify which cancer patients are most likely to benefit from radiation therapy or are at risk for toxicity.
A new genome sequence study suggests sequence conservation is more common in HPV16 isolates from individuals with cancer or pre-cancerous conditions.
An opinion piece in the Guardian argues that President Donald Trump is uninterested in science and that might not be a bad thing for the field.
The San Francisco Chronicle reports the Veterans Affairs Health System is studying whether genetic testing can help prescribe better depression therapies.
Stat News reports that Spark Therapeutics' Luxturna is now being used to treat a wider array of patients.
In Genome Biology this week: transcription factor use among brittle stars, single-cell RNA sequencing strategy, and more.